Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES. Travis LB, et al. Among authors: joensuu t. J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65. doi: 10.1093/jnci/dji278. J Natl Cancer Inst. 2005. PMID: 16174857
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.
Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E. Travis LB, et al. Among authors: joensuu t. J Natl Cancer Inst. 2002 Feb 6;94(3):182-92. doi: 10.1093/jnci/94.3.182. J Natl Cancer Inst. 2002. PMID: 11830608
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years.
Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van't Veer MB, Stovall M, Gospodarowicz M, Travis LB. Dores GM, et al. Among authors: joensuu t. J Clin Oncol. 2002 Aug 15;20(16):3484-94. doi: 10.1200/JCO.2002.09.038. J Clin Oncol. 2002. PMID: 12177110
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.
Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, Van't Veer MB, Joensuu T, Storm H, Stovall M, Boice JD Jr, Gilbert E, Gail MH. Travis LB, et al. Among authors: joensuu t. J Natl Cancer Inst. 2005 Oct 5;97(19):1428-37. doi: 10.1093/jnci/dji290. J Natl Cancer Inst. 2005. PMID: 16204692
Lung cancer after treatment for Hodgkin's disease: focus on radiation effects.
Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, Lynch CF, Curtis RE, Holowaty E, Storm H, Pukkala E, van't Veer MB, Fraumeni JF, Boice JD Jr, Clarke EA, Travis LB. Gilbert ES, et al. Among authors: joensuu t. Radiat Res. 2003 Feb;159(2):161-73. doi: 10.1667/0033-7587(2003)159[0161:lcatfh]2.0.co;2. Radiat Res. 2003. PMID: 12537521
Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A; FinnProstate Group. Hackman G, et al. Among authors: joensuu t. Eur Urol. 2019 Nov;76(5):586-595. doi: 10.1016/j.eururo.2019.07.001. Epub 2019 Jul 30. Eur Urol. 2019. PMID: 31375279 Clinical Trial.
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.
Lehtonen M, Sormunen J, Luukkaala T, Marttila T, McDermott R, Joensuu T, Lehtinen I, Ginman C, Kellokumpu-Lehtinen PL. Lehtonen M, et al. Among authors: joensuu t. Acta Oncol. 2022 Aug;61(8):963-971. doi: 10.1080/0284186X.2022.2098680. Epub 2022 Jul 18. Acta Oncol. 2022. PMID: 35847998 Free article. Clinical Trial.
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H; PROSTY study group. Kellokumpu-Lehtinen PL, et al. Among authors: joensuu h, joensuu t. Lancet Oncol. 2013 Feb;14(2):117-24. doi: 10.1016/S1470-2045(12)70537-5. Epub 2013 Jan 4. Lancet Oncol. 2013. PMID: 23294853 Clinical Trial.
142 results